In a press statement, Grant G Behrman, Managing Partner at Behrman Capital, said: “Vista Apex is a proven company with a track record of success in the healthcare sector. Its innovative in-house research team and trusted customer relationships support a strong business, well-positioned for further expansion.”
Aliya Khaydarova, Managing Principal at Inverness Graham, added: “Vista Apex was our second dental platform at Inverness Graham and second time partnering with our long-term Senior Operating Partner and dental industry expert Garrett Sato.
“Together with Garrett, we proactively identified Vista Dental as a potential platform and developed the strategy to transform the company into a broader dental solutions provider. Through our proprietary sourcing efforts, we identified and closed on three add-on acquisitions that significantly increased the breadth of Vista Apex’s product offerings, expanded the company’s total addressable market and provided significant opportunities for both revenue and cost synergies.”
Vista Apex and Inverness Graham were advised by Lazard Frères & Co.
Behrman Capital was founded in 1991 by Grant G and Darryl G Behrman, with investments focusing on defence and aerospace, healthcare and specialty industrials. The firm has raised $4.1bn since inception and is currently investing out of its seventh fund.
Inverness Graham was founded in 1996 and invests in high-growth businesses across healthcare, tech-enabled services, software and advanced manufacturing.
Source:Private Equity Wire
Can’t stop reading? Read more
Permira pivots Asia strategy toward India, winding down China offices amid regional reshuffle
Permira pivots Asia strategy toward India, winding down China offices amid regional reshuffle...
KKR appoints Morgan Stanley for potential Logisteed IPO in Tokyo as Japan’s listing market heats up
KKR appoints Morgan Stanley for potential Logisteed IPO in Tokyo as Japan’s listing market heats...
Private equity in 401(k)s: who it suits—and who should steer clear
Private equity in 401(k)s: who it suits—and who should steer clear As private equity becomes more...